ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1354

Successful Self-Administration Of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen

Jaime Pachon1, Alan Kivitz2, Kay-Uwe Heuer3 and Uwe Pichlmeier3, 1Arthritis and Rheumatic Care Center, Miami Research Associates, South Miami, FL, 2Altoona Center for Clinical Research, Duncansville, PA, 3medac GmbH, Wedel, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: DMARDs, methotrexate (MTX), Psoriatic arthritis, rheumatic disease and rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Predictors of Disease Course in Rheumatoid Arthritis - Treatment Approaches

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Methotrexate (MTX) is the most commonly used and recommended DMARD for the treatment of RA. SC administered MTX is well absorbed and appears to overcome the problems associated with oral administration, including variable absorption and saturation of the absorption mechanism with increasing doses.

The purpose of this study was to assess the usability, label comprehension, robustness, safety, and bioavailability of SC self-administration (SA) of the prefilled MTX pen containing 0.3 mL of MTX 50 mg/mL solution (medac GmbH, Germany) in a typical population of RA patients requiring MTX treatment. 

Methods: The study population consisted of 104 patients aged 16 years or older, including newly diagnosed and MTX naïve and those switching from an oral route of administration, or those already receiving an off-label SC route of administration.

The actual use study was performed at 5 sites over a 2-week period.

Visit 1 (V1) consisted of training on the use of the device followed by an actual self-injection. Training and SA were carefully documented by a 10-item questionnaire.

Visit 2 (V2)(8-10 days after V1) consisted of a written examination for assessing patient’s retention of information and a panel of the following 4 scenario test case observations, including an actual self-injection: 1) Holding the needle in place for approximately 5 seconds, 2) Checking the window of pen to confirm MTX delivery, 3) Performing the skin pinch in preparation for self-administration, and 4) Proper disposal of pen following self-administration.

Ease of performance of each scenario was also judged by the patients. A subjective measures questionnaire was used to record patients’ impressions, difficulties, and general comments on the device.

Bioavailability was assessed in 25 patients. Stratified by body weight categories, patients were randomly assigned to either inject MTX in the abdomen or in the upper thigh.

Results:

  • After training at V1, 12 patients had questions about the MTX pen, 4 patients required assistance to perform the self-injection
  • At V2, 98.1% of patients scored 80% or better on their written examination
  • The successful completion rates of scenarios 1 through 4 were 96.2%, 100%, 98.1%, and 100%, respectively
  • For the respective test scenarios, 91.3%, 98.1%, 99%, and 100% of patients did not require any assistance
  • The mean rating of easy performance for each test case scenario was 9.8 or higher on a 1 to 10 scale with 1 being very difficult and 10 being very easy
  • The subjective measures questionnaire indicated that patients felt the MTX pen was easy to use and their overall impression was favorable
  • After use, all the MTX pens were intact and had reliably delivered 0.3 mL MTX
  • PK analysis revealed that excessive body weight (>100 kg) significantly decreased both AUC and Cmax of MTX when administered SC to the abdomen
  • No adverse device effects, unanticipated adverse device effects, deaths, serious adverse events, or adverse events leading to study drug discontinuation were reported

Conclusion:

The MTX pen was consistently and reliably used by the intended population with a high degree of effectiveness, patient satisfaction, and safety.


Disclosure:

J. Pachon,

Pfizer Inc,

8,

Takeda,

8,

UCB,

8,

medac,

2;

A. Kivitz,
None;

K. U. Heuer,

medac,

3;

U. Pichlmeier,

medac,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/successful-self-administration-of-methotrexate-in-rheumatoid-arthritis-patients-using-a-prefilled-autoinjector-pen/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology